CardiaTec has secured a £1.4 pre-seed investment to further develop its artificial intelligence cardiovascular disease treatment.
CardiaTec, a Cambridge-based health tech startup, is developing a platform using artificial intelligence to make sense of large-scale cardiovascular data. The startup covers every level of biology such as methylation, gene variation and metabolic functions.
Thanks to the new investment, CardiaTec is exploring Target-Drug interactions to deliver an effective treatment to patients in a cheaper and faster way.
“Cardiovascular disease research has been subject to some very positive recent events,” said Raphael Peralta, CEO of CardiaTec.
“We strongly believe, after several decades of stagnated investment and innovation, cardiovascular disease is re-emerging with newfound interest, driven by the application of artificial intelligence in being able to drive new and meaningful insights to help meet patients’ needs,” he added.
The investment was led by APEX Ventures and Laidlaw Scholars Ventures (LSV). This funding represents the first investment for LSV.
“We are delighted to support this exceptional team on their mission to improve patient outcomes by using artificial intelligence for good,” said Niall Santamaria, chief investment officer at LSV.
“Despite the prevalence of cardiovascular ailments, there has been significant under-investment, so we believe these funds will provide CardiaTec with the opportunity to unearth treatments that make a real difference to patients.”
Cardiovascular disease is a general term for conditions affecting the heart or blood vessels. This include conditions such as coronary heart disease, strokes, peripheral arterial disease and aortic disease.
Cardiovascular disease is one of the main causes of death and disability in the UK, but it can usually be prevented by conducting a healthy lifestyle.
CTO at CardiaTech Namshik Han said “Recent advantages in artificial intelligence are generating novel ways to interpret multiomic data. I am excited to lead CardiaTec’s technology strategy to establish a new paradigm for understanding the pathophysiology of cardiovascular diseases.”
